EDAP 241220 2.50C (EDAP241220C2500) Stock Options, News & Quotes

0.10
0.000.00%

15min DelayClose Dec 20 16:00 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 4 18:33

NEWS TODAY

$EDAP TMS (EDAP.US)$
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer
EDAP TMS SA (Nasdaq: EDAP) announced the publication of the HIFI study results in European Urology, comparing Focal One® Robotic HIFU to radical prostatectomy (RP) for localized prostate cancer treatment. The landmark study, involving 3,328 patients across 46 centers, demonstrated that Focal One Robotic HIFU is non-inferior ...

Jaguar8

Sep 19 07:22

NEWS

$EDAP TMS (EDAP.US)$
EDAP and Avenda Health Launch World’s First AI-Assisted Focal One® Robotic HIFU Procedures
EDAP TMS SA (Nasdaq: EDAP) and Avenda Health have launched the world's first AI-assisted Focal One® Robotic HIFU procedures for prostate cancer treatment. The collaboration integrates Avenda's FDA-cleared Unfold AI® technology with EDAP's Focal One robotic HIFU platform. Unfold AI creates 3D patient-specific cancer maps, enabling more precise tumor targeting and healthy tissue prese...

Jaguar8

Jul 19 15:16

NEWS

$EDAP TMS (EDAP.US)$
EDAP Announces Interim Results from Phase 3 Study Evaluating Robotic HIFU for the Treatment of Deep Infiltrating Endometriosis
EDAP TMS SA (Nasdaq: EDAP) announced interim results from its Phase 3 study evaluating robotic High-Intensity Focused Ultrasound (HIFU) therapy for deep infiltrating endometriosis.
The study, involving 60 patients, aimed to assess acute pelvic pain levels. Key findings include:
1. Robotic HIFU therapy maintained an excellent safety profile, confi...

Moomoo AI

Jan 25 18:22

Despite EDAP TMS' promising revenue outlook, it's not boosting its P/S as expected. Shareholders seem skeptical of forecasts, accepting lower selling prices. The steady P/S ratio with the industry hints at anticipated revenue instability, normally a share price booster.

Investors Still Aren't Entirely Convinced By EDAP TMS S.A.'s (NASDAQ:EDAP) Revenues Despite 25% Price Jump

Moomoo Breakfast US

Sep 23, 2022 07:59

Columns Today's Pre-Market Stock Movers: QCOM, BA, ROKU, AZN and More

Gapping up
In reaction to earnings/guidance:
• $CalAmp (CAMP.US)$ +0.6%
Other news:
• $Cano Health (CANO.US)$ +6.1% ( $Humana (HUM.US)$ in the running to acquire CANO according to WSJ)
• $Corcept Therapeutics (CORT.US)$ +4.5% (extends deal with Optime Care to March 31 2024)
• $LPL Financial (LPLA.US)$ +4.1% (reports monthly activity for August)
• $Dentsply Sirona (XRAY.US)$ +3% (names new CFO)
• $iPath Series B S&P 500 VIX Short-Term Futures ETN (VXX.US)$ +2.9% (tr...